Kelly CRISPR & Gene Editing Technology ETF Rating $7.38 0.00 (0.00%) (As of 11/21/2024 ET) Add Compare Share Share Ratings Stock AnalysisChartHeadlinesOptions ChainRatingsTrends Kelly CRISPR & Gene Editing Technology ETF Aggregate Rating and Price Target (2024)How MarketBeat Aggregates ETF Rating and Price TargetMarketBeat calculates the aggregate rating and price target for an ETF by considering the weight of each stock in its portfolio. These ratings and price targets are based on the most recent ratings given by Wall Street analysts over the past year. The aggregate rating reviews the ETF's overall performance and is categorized as strong sell, sell, reduce, hold, moderate buy, buy, or strong buy. The aggegreate price target represents the average potential upside for the consensus price target of individual holdings in the ETF.XDNA Aggregate RatingModerate Buy 2.74Holdings in XDNA have an aggregate rating of Moderate Buy based on 298 analyst ratings issued in the past year covering 21 companies (94.6% of the portfolio).XDNA Aggregate Price Target$7.38High Prediction$7.38Average Prediction$7.38Low Prediction$7.38Holdings in XDNA have an aggregate price target of $7.38 and a range of $7.38 to $7.38 covering 21 companies (94.6% of the portfolio).XDNA Consensus Ratings of HoldingsStrong Buy0 Strong Buy rating(s)Buy4 Buy rating(s)Moderate Buy15 Moderate Buy rating(s)Hold2 Hold rating(s)Reduce0 Reduce rating(s)Sell0 Sell rating(s)Strong Sell0 Strong Sell rating(s) Ratings for Stocks Held by Kelly CRISPR & Gene Editing Technology ETF Strong Sell Sell Reduce Hold Moderate Buy Buy Strong Buy Ratings for the Top 21 XDNA Holdings Export to ExcelWeight In ETFCompanyShare PriceMarketRank™Consensus Rating ScoreConsensus Price TargetPossible UpsideNumber of RatingsIndicator(s)ViewRatings11.05%NTLAIntellia Therapeutics$13.86+5.6%4.5521 of 5 stars2.72$54.94 296.3%18Analyst ForecastAnalyst Revision10.70%TMOThermo Fisher Scientific$515.26+0.5%4.9906 of 5 stars2.86$649.33 26.0%22Buyback AnnouncementPositive News9.57%BEAMBeam Therapeutics$23.52-4.0%2.9756 of 5 stars2.75$44.91 90.9%128.64%CRSPCRISPR Therapeutics$46.25-2.1%1.7973 of 5 stars2.37$74.94 62.0%196.78%CRBUCaribou Biosciences$1.98+1.0%2.9294 of 5 stars3.00$11.25 468.2%3Gap Up5.63%VERVVerve Therapeutics$4.60+1.1%2.4495 of 5 stars3.00$25.75 459.8%45.16%SGMOSangamo Therapeutics$1.97+1.0%2.188 of 5 stars2.67$7.00 255.5%3Analyst Revision4.73%PRMEPrime Medicine$2.993.0894 of 5 stars2.89$13.25 343.1%9Analyst Revision4.37%ABBVAbbVie$172.18+2.6%4.9637 of 5 stars2.90$203.37 18.1%21Analyst ForecastPositive News4.13%EDITEditas Medicine$2.37-1.7%4.7031 of 5 stars2.54$9.08 283.3%13Short Interest ↓4.10%ALLOAllogene Therapeutics$2.11+2.9%2.8038 of 5 stars2.75$9.73 361.3%12Short Interest ↓3.32%PSTXPoseida Therapeutics$2.724.0501 of 5 stars3.00$15.00 451.0%22.96%DTILPrecision BioSciences$6.50-9.5%4.1319 of 5 stars3.00$39.50 507.7%2High Trading Volume2.87%TSVT2seventy bio$3.16+1.6%2.7498 of 5 stars2.56$9.00 184.8%92.40%AAgilent Technologies$131.94+2.6%3.9765 of 5 stars2.50$144.36 9.4%14Upcoming EarningsDividend IncreaseNews Coverage2.10%BMYBristol-Myers Squibb$58.22+0.6%4.7946 of 5 stars2.20$54.07 -7.1%20Analyst Revision2.00%ILMNIllumina$137.09+4.1%4.6 of 5 stars2.67$164.00 19.6%24Positive News1.53%VRTXVertex Pharmaceuticals$449.32-0.4%4.0614 of 5 stars2.53$499.12 11.1%30Analyst DowngradeNews CoveragePositive News1.29%REGNRegeneron Pharmaceuticals$745.48+0.3%4.8105 of 5 stars2.78$1,099.55 47.5%23Positive News0.69%QGENQiagen$42.33+0.6%4.2776 of 5 stars2.60$50.88 20.2%100.57%BIIBBiogen$158.43+1.6%4.8686 of 5 stars2.54$257.20 62.3%28Analyst Downgrade This page (NASDAQ:XDNA) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kelly CRISPR & Gene Editing Technology ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share Kelly CRISPR & Gene Editing Technology ETF With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free XDNA Stock Alerts